Omapatrilat for the management of heart failure and hypertension
Husereau D R
Record ID 32001000955
English, French
Authors' objectives:
To summarise the available evidence on the use of omapatrilat for the management of heart failure and hypertension.
Authors' recommendations:
- Omapatrilat, first in a new class of cardiovascular drugs called vasopeptidase inhibitors, is under evaluation for the management of hypertension and heart failure.
- Several small trials have demonstrated the efficacy and tolerability of once-daily omapatrilat in the treatment of mild to moderate hypertension. Efficacy data from one medium-sized trial have demonstrated a benefit comparable to lisinopril in the treatment of systolic heart failure.
- The benefits and risks of omapatrilat as compared to ACE inhibitors are under evaluation and could affect future clinical therapy guidelines for managing hypertension and heart failure.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/research/index.html
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Heart Diseases
- Hypertension
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.